Pane wikiwiki
Hou 2026 pore-formation research shows why purity certificates can't predict membrane activity, and which functional assays close the gap.
No ke aha i pau ʻole ai ka hoʻomaʻemaʻe maʻemaʻe-mua o ka hoʻolālā ʻana o ka pore-forming peptide

ʻO ke kumu hoʻokuʻu kumu nui no kahi peptide hana membrane he helu hoʻokahi: hoʻomaʻemaʻe wahi HPLC, maʻa mau ma luna a ma luna paha 95%, me kahi kiko kiko e hōʻoia ana i ka nuipa paʻa i manaʻo ʻia. Pono maoli kēlā maʻamau, a he mea pono ke hoomaopopo pono i ka mea i kukuluia. Hōʻike ʻo RP-HPLC i ka maʻemaʻe chromatographic, 'o ia ho'i ka māhele o nā mea e ho'omoe ana i ka UV e noho ana ma ka piko nui, ʻoiai e hōʻike ana ka nuipa spectrometry i ka nuipa a, me MS/MS, kākoʻo hoʻokaʻawale pae kaʻina (Mokuna hana PMC). Pane lākou i kahi nīnau maoli: ka mea i hanaia, a pehea ka maemae.
ʻO nā tiers pono'ī nā kuʻikahi ma mua o nā koi. Hoʻopuka pinepine nā mea kūʻai aku i ka ≥95% RP-HPLC wahi ma ke ʻano he papa noiʻi., ≥98% e like me ka noiʻi hou a me ka papahele GMP, a me ≥99% no ka uku a i ʻole nā mea lapaʻau (peptide hoʻomaʻemaʻe kumu kuhikuhi, 2025). Ua hōʻike ʻia kēia mau mea kūʻai aku, ʻaʻole he mana hoʻopiʻi.

Ua lilo ka manaʻo i mea nui no ka mea he maʻalahi, wikiwiki, ʻoʻoleʻa, a lawa no ka hapa nui o nā pahuhopu non-membrane. ʻO ka hana analytical-chemistry kona kumu, ʻaʻole biophysics, kahi i ʻike ʻia ai nā palena hoʻāʻo maʻemaʻe peptide mua: ʻAʻole inoa ka hoʻomaʻemaʻe pākēneka i nā mea haumia i kāpae ʻia.
⚠️ ʻŌlelo Aʻo: ʻAʻole i helu ka maʻemaʻe hapa pakeneka i nā kaʻina holoi, ʻoki ʻoki, hui pū ʻana i nā diastereomers, counterions (TFA, acetate, chloride) a i ʻole ka wai, no laila hiki ke ʻokoʻa ka ʻike peptide net mai ke kaumaha o ka lepili (alakaʻi hoʻomaʻemaʻe peptide, 2026).
Hoʻohuihui Peptide No laila, hiki i ʻelua mau laʻana o ka nuipa inoa like ke lawe i nā manaʻo kūpono like ʻole, a ʻaʻohe palapala hōʻike e haʻi iā ʻoe inā hoʻokomo ka peptide, oligomerizes, a i ʻole e hana i kahi pore paʻa i loko o kahi membrane.
He aha ka 2026 Hōʻike maoli ʻia ka noiʻi Pore-Formation
Hoʻomaka ʻia kēlā hoʻoponopono hou ʻana me ka 2026 Nature Chemical Biology aʻo mai Deb a me nā hoa hana, ka mea e mālama i ka hoʻolālā peptide pore-forming ma ke ʻano he waiwai i hoʻopili ʻia ma mua o kahi hopena hoʻomaʻemaʻe.. Holo ka hui 51 µs o ka hoʻoikaika kino molekala kalahala ʻole (Martini 2.2 / GROMACS) ma ka ʻaneʻane 150 ʻO nā pores octameric transmembrane i hui mua ʻia ma POPC, hōʻoia i nā trajectories me 2 µs nā hoʻohālikelike ʻātoma āpau, a laila synthesized 22 peptides a hoʻāʻo iā lākou e ka calcein leakage, planar bilayer electrophysiology, AFM manawa maoli, CD, a me GUV dextran halihali (ʻAhahui Peptide ʻAmelika, 2026-08-06).
He mea nui nā hopena ʻelua no ka hoʻoponopono ʻana i ke kaʻina. Ka mua, Ua hiki mai ka conductance ma nā ʻanuʻu ʻokoʻa: kokahi-pore waiwai o 0.116, 0.251, 0.353, a 0.424 nS (ʻAhahui Peptide ʻAmelika, 2026-08-06). ʻO kahi pahu pahu pahu, kahi e laina ai nā peptides i kahi ala paʻa, a he pore toroida, kahi o ka lipid bilayer pono'ī e piʻo i loko o ka uhi, hana i nā pūlima conductance like ʻole, no laila, ʻo ke ʻano stepwise he heluhelu ʻana o ka hoʻolālā, ʻaʻole wale i ka nui o ka peptide i hoʻopaʻa ʻia. Ka lua, Loaʻa ka AFM i nā pores i ka manawa maoli 6 nm akea maloko 20 mau minuke o ka hoʻohui peptide (ʻAhahui Peptide ʻAmelika, 2026-08-06).
Ua hoʻoheheʻe ʻia ka pipeline 52 ʻae ʻia nā ʻōkuhi kaʻina i nā papa ʻehā, Hoʻonohonoho ʻia e ka nui o ka pilina mai kahi 150-peptide MD scan (ʻAhahui Peptide ʻAmelika, 2026-08-06). E heluhelu i kēlā mau helu e like me nā kūlana assay, aole mau: ʻO kēlā me kēia waiwai conductance no kahi kumu hoʻohālike bilayer kikoʻī, ikaika ionic, a me ka uila, a ʻaʻohe o lākou e hoʻololi pololei i kahi ʻōnaehana membrane ʻē aʻe.
Pehea e neʻe ai ka hoʻoponopono ʻana i kahi peptide ma waena o nā pore Phenotypes

ʻO ka ʻāpana e hoʻololi i ke kaʻina peptide a me ka hana membrane ʻo ia ke pani, ʻaʻole ka peptide. Hiki i nā hoʻoponopono hoʻokahi a hui pū ke hoʻoneʻe i hoʻokahi iwi kuamoʻo ma waena o ʻekolu mokuʻāina: ʻaʻohe hana membrane, leakae kuewa, a he pore paa.
ʻO ka hoʻokomo ʻana i nā mea ʻala ka lever maopopo loa. Ma nā hoʻolālā a Deb et al, ua hoʻololi ʻia nā kūlana ʻala maikaʻi mai nā koena 13 a 19 i loko o 30-koena kumu i 13, 15, 8 a 26 i ka manawa i hoopokoleia ke kumu i 22 koena, a hoʻololi ʻia ka helix tilt mai 50 ° a 30 ° pili i ka membrane maʻamau (ʻAhahui Peptide ʻAmelika, 2026-08-06). Hiki ke pani i ka uku no kēlā heleuma: ʻEhā mau alahaka paʻakai Arg-Asp no kēlā me kēia interface i mālama i ka pono pore me ka wehe ʻana i ka hoʻopaʻa ʻala. (ʻAhahui Peptide ʻAmelika, 2026-08-06). Hoʻonohonoho nā electrostatics i ka ikaika hoʻokele, ʻoiai ua hōʻike ʻia nā peptides cationic 20 kJ mol⁻¹ pili nui no ka anionic POPE:POPG ma mua o zwitterionic POPC bilayers (ʻAhahui Peptide ʻAmelika, 2026-08-06).
ʻO Stereochemistry kahi koʻi lua kūʻokoʻa. ʻO ka hoʻololi ʻana i kēlā me kēia koena o DpPorA i kāna D-enantiomer i hoʻololi i ka hana hoʻokahi mai kahi kokoke 4 nS i 1.5 ± 0.3 nS ma +100 mV i loko 1 M KCl (n = 75), a ma kela aoao 100 hoʻokomo i ka māhele D-form 75%/25% ma waena o nā mokuʻāina ~1.5 nS a me ~4 nS me PK⁺/PCl⁻ ≈ 7:1 (ʻO Ge et al., Nat Common, 2022-09-14).
|
Hiʻona kaʻina |
Ka hopena membrane i manaʻo ʻia |
ʻO ka ʻike e ʻike ai |
|---|---|---|
|
Helicity |
Hiki paha i ka peptide ke span i ka bilayer ma ke ʻano he helix mau |
ʻO ka dichroism pōʻai ma POPC vs POPE:POPG vesicles |
|
Ka manawa hydrophobic |
ʻO ka hohonu a me ke kūpaʻa o ka hoʻokomo ʻana o ka membrane |
ʻO ka hoʻololi ʻana o ka tryptophan fluorescence; kinetics leakage vesicle |
|
Hoʻokomo kālā |
Lipid-headgroup koho a me ka paʻakai-alahaka stabilization |
Zeta hiki; conductance ma anionic vs zwitterionic bilayers |
|
Hoʻokomo ʻala |
ʻO ka heleuma waena a me ka helix tilt |
Oriented circular dichroism; paʻa-mokuʻāina NMR kihi kihi |
|
Geometry a me ke kikoo |
ʻO ke ʻano o ka hale hana: pahu pahu, toroida a i ʻole β-pepa |
Hoʻokahi-kanal conductance; CD pili; FTIR amide I |
ʻO Lysine, ʻO nā koena arginine a me bulkier e hana ma ke ʻano he mau kiaʻi puka membrane-desorption, ke ālai ʻana i ka hoʻokomo hohonu a i ʻole ka unuhi nui ʻana (PMC, 2021-12-24).
No ke aha i hiki ʻole ai i ka hoʻāʻo maʻemaʻe ke wānana i ke ʻano o ka membrane
Ua ʻike mua paha ʻoe i kēia: ʻelua hue, like nominal mass, palapala like like, a ʻo kekahi o lākou ʻaʻole i hana e like me ka ʻōlelo a ka assay e pono ai. ʻAʻole hewa ka palapala hōʻoia. ʻO ka pane ʻana i kahi nīnau haiki ma mua o ka nīnau āu e nīnau nei.
Hoʻokumu ʻia ka HPLC a me ka spectrometry i ka ʻike a me ka maʻemaʻe chromatographic. ʻAʻole hoʻokumu ʻia ka paʻi a i ʻole ke kūkulu lua, mokuʻāina oligomeric, kūlana hui ma lalo o nā kūlana maoli, a i ʻole ka hana membrane; Pono kēlā mau mea i nā ho'āʻo biophysical a i ʻole nā cell-based assays (PMC analytical loiloi). Lawe pū ka hoʻomaʻemaʻe hapa pākēneka i ka counterion a me ke koena-wai huikau, no laila hiki i ʻelua mau laʻana o ka nui helu like ke hāʻawi i nā ʻano ʻokoʻa kūpono i ka wā i hoʻoheheʻe ʻia. ʻO ka ʻike ʻokoʻa kūpono ʻo ia ka hana membrane ʻokoʻa, ʻoiai ke ʻano like ke kaʻina.
Haʻalulu nā hopena hana no ko lākou mau kumu ponoʻī. Ke neʻe pinepine ʻia nā kumu waiwai hoʻoneʻe haʻahaʻa liʻiliʻi e hoʻokahi a ʻelua ʻanuʻu dilution ma waena o nā laboratories, mea hoʻohana a me nā ʻano hana, a haʻalele i nā mana, ka hoʻohana ʻana i ka inoculum hewa (i hoakakaia e like me 5 × 10⁵ CFU/mL) a i ʻole ka haʻalele ʻana i nā kūlana ulu hiki ke hoʻololi i nā hopena (Ka nānā ʻana i nā ʻano MIC, 2024). Hoʻonui ka pilikia reproducibility i ka wānana: ma kahi 2026 benchmark o 48 paʻi ʻia nā ʻano wānana antimicrobial-peptide, emi mai 25% hiki ke hana hou (ʻO ka hōʻailona BATTLE-AMP, bioRxiv, 2026). ʻO ia kahi hōʻailona preprint o nā ʻano hana, ʻaʻole o nā peptides, akā hoʻonohonoho i nā manaʻolana no ka nui o ka hoʻoholo hoʻolālā e hiki ke hoʻoholo ʻia ma ka pepa.
ʻO kēia kahi e pau ai ka peptide characterization a hoʻomaka kāu hana ponoʻī.
Ki Takeaway: ʻO ka hoʻāʻo hoʻokuʻu analytical he ʻaoʻao kūʻai; ʻO ka hoʻāʻo ʻana o ka membrane-ʻaoʻao o ka mea kūʻai aku.
ʻOi aku ka maikaʻi no ka hoʻolālā ʻana i ka pore-forming peptide
E hoʻolālā i nā peptides pore-forming e kū'ē i kahi hoʻolālā pore i hoʻopaʻa ʻia a me kahi hoʻāʻo ʻana, ʻaʻole kūʻē i kahi kikoʻī maʻemaʻe. ʻO kēlā hoʻololi hoʻokahi i ka pahuhopu hoʻolālā e hoʻonohonoho hou i ka papahana holoʻokoʻa.
ʻElima mau loina hahai mai ka 2026 ʻikepili:
-
E koho mua i ka hale hana. E hoʻoholo inā makemake ʻoe i kahi pahu pahu, toroidal, a i ʻole ka pore i hoʻopā ʻia ma mua o kou pā ʻana i ke kaʻina, no ka mea, e pili ana kēlā me kēia hale hana i kahi ʻokoʻa o nā kaohi kaʻina.
-
E mālama i kahi hoʻokomo ʻala a me nā alahaka paʻakai ma ke ʻano he papa paʻa. Hoʻoponopono lākou i ka lōʻihi o ka hui ʻana o ka hui i loko o kahi membrane, ʻaʻole i ka ikaika o ka paʻa ʻana.
-
E mālama i ka hoʻokomo ʻana i ka uku e like me ka papa koho. Ma kahi e noho ai nā koena cationic e pili ana i ka hoʻonohonoho ʻana o ka maka hydrophobic e hoʻokaʻawale ai ka peptide ma waena.
-
E mālama i ka stereochemistry ma ke ʻano he hoʻololi phenotype. ʻAʻole he footnote ka hoʻololi ʻana i ka waika D-amino; hiki iā ia ke hoʻoneʻe i kahi peptide ma waena o nā pore phenotypes.
-
E hoʻopaʻa mua i ka heluhelu hana ma mua o ka synthesis. E hoʻoholo i ka hoʻāʻo, ka ʻōnaehana lipid, a me ka peptide-to-lipid ratio ma mua, so the synthesis batch has something to be tested against.
The proof point is that this is workable at scale. A 2026 design pipeline moved from a 150-peptide in-silico scan to 22 synthesized peptides, with calcein leakage and computed pore hydration correlating across the set. The lead peptide, KDFA2i + 9-NH₂, produced roughly 20% calcein release at a peptide-to-lipid ratio of 1:2,000, rising at higher ratios (ʻAhahui Peptide ʻAmelika, 2026). Note what that number is: a functional result at a defined ratio in a defined system, which is exactly the kind of evidence a certificate of analysis cannot supply.
For teams without in-house synthesis, MOL Changes supports custom sequence design and modification work, which can be used to turn a chosen architecture into an orderable peptide while the functional testing stays in your own assay.
None of this is deterministic. He probabilistic nā lula Sequence-to-pore, a ʻo kekahi mau peptides i hoʻolālā maikaʻi ʻia e hāʻule i kā lākou hoʻāʻo mua. ʻO ka waiwai o ka framework ka mea e hoʻomaopopo ai i ka hemahema ma mua o ka pohihihi.
Ke koho ʻana i nā hōʻike hana e hoʻokō i ka ʻikepili maʻemaʻe

ʻO ka hana mua e koho i ka assay e pane i ka nīnau maʻemaʻe hiki ʻole ke hoʻāʻo: ʻaʻole "ka mea i loko o kēia hue,"akā "he aha ka hana a kēia peptide i kahi membrane." No ka mea ʻO nā Peptides Synthetic nā hoʻokolohua hana no nā peptides hana membrane, ʻo ia hoʻi ka hoʻohālikelike ʻana i ka heluhelu ʻana i ka waiwai pore ma lalo o ka hoʻāʻo ʻana ma mua o ka hoʻokaʻawale ʻana i kēlā me kēia pā heluhelu manuahi.
ʻO ka leaka ʻo Calcein e ana i ka hoʻokuʻu ʻana i ka wai mai nā vesicle lipid a hōʻike i ka permeabilization nui. ʻO ka depolarization ʻo DiSC₃-5 ke ʻimi nei i ka nalo ʻana o ka hikina membrane ma waena o kahi membrane bacteria, no laila ke hōʻike nei i ka hoʻohaunaele membrane i kahi pōʻaiapili physiological. Hoʻopaʻa ʻia ka hoʻopaʻa ʻana o ka hoʻopaʻa ʻana i ke ala hoʻokahi i kēia manawa ma ka puka hoʻokahi i ka manawa, ʻo ia wale nō ka mea o nā mea ʻekolu e hoʻoholo ai i ka hana hoʻokahi.
Noho nā ʻekolu ma nā unahi ʻokoʻa loa. Pono ka lele ʻana o Calcein i nā ʻano peptide i loko o ka 1 i 25 µM e kūʻē i kahi ʻano 20 µM lipid me 75 mM calcein intraliposomal, ʻoiai ʻo DiSC₃-5 nā hopena depolarization e hui pū ana a puni 19 µM. Hiki i ka hana kaila hoʻokahi i ka sub-micromolar a i ka haʻahaʻa micromolar, me nā ʻike i paʻi ʻia ma 0.3 µM, 0.8 i 4.1 µM, a 6.2 µM, hoʻoholo i nā conductances mai kahi 6 i 360 pS a hiki i ka laulā nanosiemens. ʻO kahi peptide i ʻike ʻole ʻia i ka leakage assay aia paha ma lalo o ka papahele ʻike o kēlā heluhelu..
|
Hoʻāʻo |
Nīnau ia pane |
Pono ka mana |
wahi makapō |
|---|---|---|---|
|
Ka leaka ʻana o Calcein |
Hoʻopili ka peptide i nā bilayers lipid i ka nui? |
ʻO nā vesicle me ka peptide ʻole; mea holoi no 100% hoʻokuʻu |
Hoʻokaʻawale ʻia nā pores transient a i ʻole nā pores |
|
depolarization ʻo DiSC₃-5 |
Hiki ke hāʻule i ka hiki ke membrane? |
Mana protonophore; peptide-free membrane |
ʻAʻole hiki ke hoʻokaʻawale i ka hoʻokumu ʻana o ka pore mai ka solubilization membrane |
|
ʻAla hoʻokahi-kanela hoʻokahi ʻāpana bilayer planar |
He aha ka unitary conductance a me ke ola o hoʻokahi pore? |
peptide-ʻole bilayer; holo uila-hoohuli |
Haʻahaʻa haʻahaʻa; ʻAʻole paha e hōʻike ka pore i ka heluna kanaka |
ʻAʻole hypothetical ka wahi makapō ma ka lālani mua. He D-peptide ma Wza, DcWza, i hoʻopuka i ka unitary conductance o 0.95 ± 0.1 nS ma +200 mV i loko 1 M KCl ma kela aoao 50 hanana, nae ka vesic permeabilisation ma hope o hoʻokahi hola 4.6 ± 2.5% kū'ē i ka mana o 4.2 ± 2.1% (ʻO Ge et al., Nature Communications, 2022). ʻO nā pores liʻiliʻi e hoʻokuʻu ana ma mua o ka hoʻomau ʻana e waiho ʻaneʻane ʻaʻohe wahi i loko o kahi heluhelu leakage nui. ʻO ia ke ʻano no ka holo ʻana i ka hana hoʻokahi ma ka ʻaoʻao, aole ma kahi o, vesicles assays.
Hoʻokō, i mea e:
-
E wehewehe i ke ʻano membrane a me ka hoʻohui ʻana o ka lipid. E hoʻohālikelike i ka hui lipid me ka membrane olaola āu e mālama nei. Lanakila wikiwiki: he lā heluhelu a hoʻoholo.
-
E koho i ka heluhelu heluhelu. Leaka nui no ka holo mua, depolarization no kahi pōʻaiapili physiological, kaila hoʻokahi no ka mīkini. ʻO ka wā lōʻihi: hoʻokahi-kanal rigs he mau pule no ke kauoha.
-
Hoʻoponopono i nā mana. ʻO nā vesicles ʻole peptide, he mea hoopilikia maikai, a me ka mea hoohehee wale. Lanakila wikiwiki, akā, ʻo ka hoʻokuʻu ʻana iā ia e hōʻole i nā mea a pau i lalo.
-
E hoʻopaʻa i ka pae koʻikoʻi. E hoʻolōʻihi i ʻelua mau kauoha o ka nui a puni kāu paepae i manaʻo ʻia, a hoʻomanaʻo i nā papahele ʻike ma luna.
-
E hoʻopaʻa inoa mua i ka ʻae ʻae. E kākau i ka mea i helu ʻia he ʻeleu ma mua o kou holo ʻana i ka pā. ʻO kēia ka ʻanuʻu a ka hapa nui o nā hui e lele a mihi nui.
E ana i ka leakage rate, hoʻokahi conductance, a me ka lakio koho. He ʻelua a ʻehā mau pule ka manawa kūpono no ka hoʻāʻo ʻana i ka vesicle a ʻelua a ʻekolu mau mahina ma mua o ka hoʻolaha ʻana o ka ʻikepili hoʻokahi..
Nā Hōʻike a me kahi e paʻa mau ai ka ʻike kuʻuna
ʻO nā lula hoʻolālā he probabilistic, ʻaʻole hoʻoholo, a hāʻule kekahi pores i hoʻolālā ʻia. ʻO ia ka palena nui loa e haʻi maʻalahi, no ka mea, ʻo ia ke kumu ʻoiaʻiʻo e hoʻomau ai ka noʻonoʻo maʻemaʻe mua: ana ka maemae, hiki ke hana hou, a kūʻai aku i ka hōʻoia, ʻoiai ʻo ka hana membrane ʻaʻole ia o ia mau mea. Hana ʻia ʻo Peptide
ʻOi aku ka manaʻo o ke kumuhana ma mua o ka hoʻopaʻapaʻa. No nā pahuhopu non-membrane, a i ʻole no ka nānā ʻana i nā hale waihona puke kahi e paʻa ai ka heluhelu ʻana ma mua o ka permeabilisation, ʻO RP-HPLC a me MS ka maʻemaʻe maoli ke kumu hoʻokuʻu kūpono, a ʻo nā palena hoʻāʻo hoʻomaʻemaʻe peptide e lilo wale i pilikia ke noi ʻia kēlā palapala hōʻoia e pane i kahi nīnau ʻaʻole i hoʻolālā ʻia e pane..
ʻO ka mea nāwaliwali loa o ka hihia ʻo ia ka waihona hōʻike ponoʻī. Ka nui o ka 2026 Loaʻa ke alakaʻi hoʻolālā mai kahi paipu MD coarse-grained holo i POPC, a ua hōʻike ʻia ka hoʻopakele ʻana i ke alahaka paʻakai ma ka simulation ma mua o ka hana ʻana o kekahi i ka peptide. ʻAʻole hewa kekahi hopena; ʻoi aku ka haiki ʻelua ma mua o ka manaʻo o ka lula hoʻolālā.
E noʻonoʻo i ke kāʻei e like me ke kuhiakau, ʻaʻole kahi kikoʻī. Hōʻike ʻo ia iā ʻoe i ka hoʻoponopono ʻana i ke kaʻina hana pono a me nā assays e pono ke holo, a ke manaʻo nei e hāʻule kekahi o ia mau pores.
Akā ʻaʻole ia e hōʻoiaʻiʻo i ka hana ʻana o ka Membrane Reproducible?
ʻAʻole. ʻO ka maʻemaʻe e kāohi i ka mea i loko o ka hue, ʻaʻole pehea e hui ai kēlā mea i kahi bilayer. A ≥98% kikoʻī ʻaʻole he mea ʻole, ʻoiai: hoopau ia i ka nui o na huikau, me nā kaʻina i ʻoki ʻia, holoi i nā mea haumia, a me nā huahana hoʻoheheʻe ʻana i mea e hoʻopalapala ai i ka heluhelu ʻana o nā hana. ʻO ka mea hiki ʻole ke haʻi iā ʻoe inā hoʻokomo ka peptide, oligomerizes, a i ʻole ke ʻano o ka hoʻolālā pore i manaʻo ʻia e kāu hoʻolālā.
Inā hoʻopaʻa ʻia kahi papahana i loko o kahi kahe hana hoʻokuʻu maʻemaʻe wale nō, ʻaʻole pono ʻoe e kūkulu hou i ka papahana. Hoʻohui i hoʻokahi heluhelu hana orthogonal, e like me ka hoʻokahe ʻana o ka vesicle a i ʻole ke ana ʻana i ka conductance bilayer planar, a hoʻohana iā ia e hōʻoia i ka hana ʻana o ka hailona i hoʻokuʻu ʻia e like me ka manaʻo.
E mālama i ka hana i hōʻike ʻia mai kahi peptide i hōʻike ʻia e HPLC a me MS ma ke ʻano he manawa. Me ka ʻike ʻole ʻia o nā kūlana assay a me nā mana, ʻAʻole hiki iā ʻoe ke haʻi i ka hopena i ʻike ʻia mai ka peptide, he counterion koena, a i ʻole ka pale.
Ka hopena: Mai ka Palapala Hoʻomaʻemaʻe i ka Hōʻike Hana Hana
Pono ka maʻemaʻe akā ʻaʻole lawa no ka hoʻolālā peptide pore-forming: hiki i ka chromatogram ke hōʻoia i ke ʻano o ka mole, ʻAʻole loa ka mea e hana ai ma kahi membrane.
Aia ka hoʻololi kūpono i nā pae hoʻokuʻu. No nā peptides hana membrane, Pono e hele ka ʻikepili analytical me hoʻokahi heluhelu hana, a e hōʻea nā helu hana i paʻi ʻia me nā kūlana hoʻāʻo a me nā mana i hana ai. ʻO kēlā hui ʻana ka mea e hiki ai ke hoʻopuka hou ʻia ka hopena ma nā lima o kekahi ma mua o ka lab wale nō i hana ai..
ʻAʻohe o kēia e noi iā ʻoe e kūkulu hou i kahi papahana i loaʻa. E hoʻomaka ma ka palapala ʻana i nā hiʻohiʻona kaʻina āu e hoʻokele ai i ka ʻano membrane āu e pono ai, a laila koho i ka assay e ʻike i kēlā ʻano. Hiki i ka papa hana hoʻolālā a me ka papa inoa kikoʻī ke hoʻomaopopo i ka palapala ʻāina ma mua o ke kauoha ʻana i ka ʻāpana aʻe.
ʻO ke kuhikuhi o ka huakaʻi e pili ana i nā lula hoʻolālā i hiki ke hoʻohana ʻia: maikaʻi e hōʻemi i kahi kaʻina, ʻoiaʻiʻo e ʻōlelo i ka wā e hana ʻole ai kahi pore i hoʻolālā ʻia e like me ka mea i manaʻo ʻia.

